[go: up one dir, main page]

US3867532A - Diazabicyclodecanes as anti-ulcer agents - Google Patents

Diazabicyclodecanes as anti-ulcer agents Download PDF

Info

Publication number
US3867532A
US3867532A US417368A US41736873A US3867532A US 3867532 A US3867532 A US 3867532A US 417368 A US417368 A US 417368A US 41736873 A US41736873 A US 41736873A US 3867532 A US3867532 A US 3867532A
Authority
US
United States
Prior art keywords
compound
diazabicyclo
decane
milligrams
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US417368A
Inventor
Louis D Boyajy
John H Gogerty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Wander Inc
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to US417368A priority Critical patent/US3867532A/en
Application granted granted Critical
Publication of US3867532A publication Critical patent/US3867532A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Definitions

  • the active agents with which this invention is concerned may be represented by the following structural formula:
  • R is hydrogen, fluoro, chloro or lower alkoxy, i.e., alkoxy having 1 to 4 carbon atoms, e.g., methoxy, ethoxy, isopropoxy and the like, or pharmaceutically acceptable salts thereof.
  • This invention contemplates only the novel use of the compounds of formula (I) in the treatment of ulcers and pre-ulcer conditions such as severe irritation of the gastrointestinal track.
  • the pharmaceutically acceptable salts include the non-toxic pharmaceutically acceptable acid addition salts. Such salts possess the same order of activity as the free base, are readily prepared in conventional manner by reacting the base with the appropriate acid and are included within the scope of the invention.
  • Representative of the acid addition salts are the mineral acid salts such as the hydrochloride, hydrobromide, sulphate phosphate and the like, and the organic acid salts, such as the succinate, benzoate, acetate, p-toluenesulfonate, benzenesulfonate and the like.
  • the use of the compounds of formula (I) as antiulcer agents is suggested by their autonomic profile as indicated by blood pressure changes in the anesthetized dog given 1 to milligrams per kilogram of test compounds intravenously as measured with the aid of a mercury manometer or transducer via a catheter inserted in either the carotid or femoral artery of the animal and recorded either on a kymograph or an appropriate electronic recorder.
  • the surgical method of preparing the animal is a modification of that described by Markowitz (Exper. Surgery, Williams and Wilkins, 2nd Ed., 1949).
  • the inhibition of the depressor response (fall in blood pressure) to vagal stimulation using a Grass stimulator shows a suppression of the release of acetylcholine at the parasympathetic postganalionic neuroeffector sites and indicates the compounds of formula (I) are useful in the treatment of ulcers.
  • the anti-ulcer activity of the compounds of formula (I) is indicated by the prevention of stress induced ulcers produced by cold confinement at 4C in rats given one milligram per kilogram per hour of the test compound using a modification of the technique of Brodie, D. A., et al. (Gastroenterology 38; 353. i960) and by the inhibition of gastrointestinal motility produced by vagal stimulation using a Grass stimulator in the anesthetized dog given 1 to 10 milligrams per kilogram of the test compound according to the method of Craver, B. M., et al (J. Pharmacol and Exp. Ther. 93. 168, 1948).
  • the compounds may be administered orally or parenterally as such or admixed with conventional pharmaceutical carriers. They may be administered in such forms tablets, dispersible powders, granules, capsules, syrups and elixirs ancl parenterally as solutions, suspensions, dispersions, emulsions and the like, e.g., a sterile injectable aqueous suspension.
  • the compositions may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation.
  • Tablets may contain the active ingredient in admixture with conventional pharmaceutically acceptable excipients, e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc, granulating and disintegrating agents, e.g, starch and alginic acid, binding agents, e.g., starch, gelatin and acacia, and lubricating agents, e.g., magnesium stearate, stearic acid and talc.
  • excipients e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc
  • granulating and disintegrating agents e.g, starch and alginic acid
  • binding agents e.g., starch, gelatin and acacia
  • lubricating agents e.g., magnesium stearate, stearic acid and talc.
  • the tablets may be uncoated or coated by known
  • oral liquids e.g., suspensions maycontain the active ingredient in admixture with any of the conventional excipients utilized for the preparation of such compositions, e.g., suspending agents (methylcellulose tragacanth and sodium alginate) wetting agents (lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan mono-oleate)'and preservatives (ethyl-o-hydroxybenzoate).
  • suspending agents methylcellulose tragacanth and sodium alginate
  • wetting agents lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan mono-oleate
  • preservatives ethyl-o-hydroxybenzoate
  • Capsules may contain the active ingredient alone or admixed with an inert solid diluent, e.g., calcium carbonate, calcium phosphate and kaolin.
  • the injectable compositions are formulated as known in the art. These pharmaceutical preparations may contain up to
  • the anti-ulcer effective dosage of the compounds of formula (I) employed in the treatment of ulcers and pre-ulcer conditions may vary depending on the particular compound employed and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of formula (I) are administered at a daily dosage of from about 1 milligrams to about I00 milligrams per kilogram of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 60 milligrams to about 1500 milligrams. Dosage forms suitable for internal use comprise from about 15 to about 750 milligrams of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.
  • injectable suspensions and liquid suspensions may be prepared using 9-(pchlorophenyl)- l ,5-diazabicyclo[4.3.l ]decane or 9-( pmethoxyphenyl)-l ,5-diazabicyclo[4.3. l ]decane as the grams of the active ingredient. 5 active ingredient in place of the 9-phenyl-l .5-
  • tablet capsule 9-phenyl-l ,5-diazabicyclo[4.3.l] I 100 decane hydrochloride tragacanth l0 lactose 247.5 200 corn starch 25 2O lngredlem Weigh! g talcum l5 mugncgium curate 3,5 9-phenyl-l.5-diazacyclol4.3.l]decane Total 400 mg. 300 mg.
  • tablets and capsules may be prelffigflii as a pared using 9-(p-chlorophenyl)-l,5- Sodium l r as desired diazabicyclo[4.3.l ]decane or 9-(p-methoxyphenyl)- for m l l,5-diazabicyclo[4.3. l ]decane as the active ingredient in place of the 9-phenyl-l,5-diazabicyclo[4.3.1] dec ane above.
  • Similar injectable solutions for injection may be prepared using 9-( p-chlorophenyl )-l ,5-
  • compositions are fordiazabicyclo[4.3.l]decane hydrochloride above. mulated with the indicated amount of active agent using conventional techniques.
  • the injectable suspen- EXAMPLE 6 sion and the oral liquid suspension represent formula- Syrups and Elixirs for Oral Administration tions useful as unit doses and may be administered in The following formulations for syrups or elixirs conthe treatment of ulcers.
  • the injectable suspension is taining an effective amount of active compound may be suitable for administration once or twice aday whereas formulated using conventional methods and are suitthe oral liquid suspension is suitably administered 2 to able for administration 2 to 4 times a day in the treat- 4 times per day for this purpose. ment of ulcers and pre-ulcer conditions.
  • liquid suspension 9-phenyll .5-diazabicyclo[4.3.l ]decane 200 I00 sodium carboxy methyl cellulose U.S.P. l.25 12.5 methyl cellulose 0.4 polyvinylpyrrolidone 5 lecithin 3 benzyl alcohol 0.0] magnesium aluminum silicate 47.5 flavor q.s. color q.s. methyl parahen. U.S.P. 4.5 prbpyl paraben.
  • a method of treating gastrointestinal ulcers in a mammal which comprises administering thereto an antr-ulcer effective amount of a compound of the formula:
  • R is hydrogen, fluoro, chloro or lower alkoxy or a pharmaceutically acceptable acid addition salt thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Certain bridged 1,5-diazacyclodecanes, e.g., 9-phenyl-1,5diazabicyclo(4.3.1)decanes are useful as anti-ulcer agents.

Description

United States Patent [191 Boyajy et a].
[111 3,867,532 [451 Feb. 18, 1975 DIAZABICYCLODECANES AS ANTI-ULCER AGENTS [75] inventors: Louis D. Boyajy, Parsippany; John H. Gogerty, Dover, both of NJ.
[52] U.S. Cl. 424/251 [51] Int. Cl A61k 27/00 [58] Field of Search 424/251 [5 6] References Cited UNITED STATES PATENTS 3,517,004 6/1970 Houlihan 424/251 Primary ExaminerFrederick E. Waddell Attorney, Agent, or FirmGerald D. Sharkin; Robert S. Honor; Thomas O. McGovern [5 7] ABSTRACT Certain bridged 1,5-diazacyclodecanes, e.g., 9-phenyll,5-diazabicyclo[4.3.1 ]decanes are useful as anti-ulcer agents.
6 Claims, N0 Drawings tions containing the above compounds as an active ingredient thereof.
The active agents with which this invention is concerned may be represented by the following structural formula:
where R is hydrogen, fluoro, chloro or lower alkoxy, i.e., alkoxy having 1 to 4 carbon atoms, e.g., methoxy, ethoxy, isopropoxy and the like, or pharmaceutically acceptable salts thereof.
This invention contemplates only the novel use of the compounds of formula (I) in the treatment of ulcers and pre-ulcer conditions such as severe irritation of the gastrointestinal track.
Many of the compounds of formula (1) above are known and may be prepared according to methods disclosed in the literature, for example, in US. Pat. No. 3,517,004. The compounds not specifically disclosed in the literature may be prepared by analogous methods using known starting materials.
The pharmaceutically acceptable salts include the non-toxic pharmaceutically acceptable acid addition salts. Such salts possess the same order of activity as the free base, are readily prepared in conventional manner by reacting the base with the appropriate acid and are included within the scope of the invention. Representative of the acid addition salts are the mineral acid salts such as the hydrochloride, hydrobromide, sulphate phosphate and the like, and the organic acid salts, such as the succinate, benzoate, acetate, p-toluenesulfonate, benzenesulfonate and the like.
The use of the compounds of formula (I) as antiulcer agents is suggested by their autonomic profile as indicated by blood pressure changes in the anesthetized dog given 1 to milligrams per kilogram of test compounds intravenously as measured with the aid of a mercury manometer or transducer via a catheter inserted in either the carotid or femoral artery of the animal and recorded either on a kymograph or an appropriate electronic recorder. The surgical method of preparing the animal is a modification of that described by Markowitz (Exper. Surgery, Williams and Wilkins, 2nd Ed., 1949). The inhibition of the depressor response (fall in blood pressure) to vagal stimulation using a Grass stimulator shows a suppression of the release of acetylcholine at the parasympathetic postganalionic neuroeffector sites and indicates the compounds of formula (I) are useful in the treatment of ulcers.
The anti-ulcer activity of the compounds of formula (I) is indicated by the prevention of stress induced ulcers produced by cold confinement at 4C in rats given one milligram per kilogram per hour of the test compound using a modification of the technique of Brodie, D. A., et al. (Gastroenterology 38; 353. i960) and by the inhibition of gastrointestinal motility produced by vagal stimulation using a Grass stimulator in the anesthetized dog given 1 to 10 milligrams per kilogram of the test compound according to the method of Craver, B. M., et al (J. Pharmacol and Exp. Ther. 93. 168, 1948). I
For such usage, the compounds may be administered orally or parenterally as such or admixed with conventional pharmaceutical carriers. They may be administered in such forms tablets, dispersible powders, granules, capsules, syrups and elixirs ancl parenterally as solutions, suspensions, dispersions, emulsions and the like, e.g., a sterile injectable aqueous suspension. The compositions may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation. Tablets may contain the active ingredient in admixture with conventional pharmaceutically acceptable excipients, e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc, granulating and disintegrating agents, e.g, starch and alginic acid, binding agents, e.g., starch, gelatin and acacia, and lubricating agents, e.g., magnesium stearate, stearic acid and talc. The tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. Similarly, oral liquids, e.g., suspensions maycontain the active ingredient in admixture with any of the conventional excipients utilized for the preparation of such compositions, e.g., suspending agents (methylcellulose tragacanth and sodium alginate) wetting agents (lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan mono-oleate)'and preservatives (ethyl-o-hydroxybenzoate). Capsules may contain the active ingredient alone or admixed with an inert solid diluent, e.g., calcium carbonate, calcium phosphate and kaolin. The injectable compositions are formulated as known in the art. These pharmaceutical preparations may contain up to about percent of the active ingredient in combination with the carrier or adjuvant.
The anti-ulcer effective dosage of the compounds of formula (I) employed in the treatment of ulcers and pre-ulcer conditions may vary depending on the particular compound employed and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of formula (I) are administered at a daily dosage of from about 1 milligrams to about I00 milligrams per kilogram of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 60 milligrams to about 1500 milligrams. Dosage forms suitable for internal use comprise from about 15 to about 750 milligrams of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.
The preferred pharmaceutical compositions from the standpoint of preparation and ease of administration are solid compositions, particularly hardfilled capsules and tablets containing from about 100 to 250 milliln a similar manner, injectable suspensions and liquid suspensions may be prepared using 9-(pchlorophenyl)- l ,5-diazabicyclo[4.3.l ]decane or 9-( pmethoxyphenyl)-l ,5-diazabicyclo[4.3. l ]decane as the grams of the active ingredient. 5 active ingredient in place of the 9-phenyl-l .5-
EXAMPLES I and 2 diazabicyclo[4.3.l]decane above. Tablets and Capsules Suitable For Oral Administration EXAMPLE 5 Tablets and capsules containing the ingredients indi- St il S l i f Injectign cated below may be prepared by conventional tech- 10 The following ingredients are dissolved in water for "lques and are useful in treating ulcers at a dose Of One injection and the resulting solution is filtered through tablet Capsule 2 to 4 times a ym, an appropriate medium to form a clear solution which is then sterilized. The sterile injectable solution is suitlngrediems Weight (mg) able for administration once or twice a day in the treat- 15 ment of ulcers or pre-ulcer conditions. tablet capsule 9-phenyl-l ,5-diazabicyclo[4.3.l] I 100 decane hydrochloride tragacanth l0 lactose 247.5 200 corn starch 25 2O lngredlem Weigh! g talcum l5 mugncgium curate 3,5 9-phenyl-l.5-diazacyclol4.3.l]decane Total 400 mg. 300 mg. ydrochloride 10 V Sodium alginate In a similar manner, tablets and capsules may be prelffigflii as a pared using 9-(p-chlorophenyl)-l,5- Sodium l r as desired diazabicyclo[4.3.l ]decane or 9-(p-methoxyphenyl)- for m l l,5-diazabicyclo[4.3. l ]decane as the active ingredient in place of the 9-phenyl-l,5-diazabicyclo[4.3.1] dec ane above. Similar injectable solutions for injection may be prepared using 9-( p-chlorophenyl )-l ,5-
EXAMPLES 3 and 4 diazacyclo[4.3.l ]decane hydrochloride or 9-(p- Sterile Suspension for Injection and Oral Liquid Suschlorophenyl)-l,5-diazabicyclo[4.3.l]decane hydropension chloride in place of the 9-phenyl-l,5-
The following pharmaceutical compositions are fordiazabicyclo[4.3.l]decane hydrochloride above. mulated with the indicated amount of active agent using conventional techniques. The injectable suspen- EXAMPLE 6 sion and the oral liquid suspension represent formula- Syrups and Elixirs for Oral Administration tions useful as unit doses and may be administered in The following formulations for syrups or elixirs conthe treatment of ulcers. The injectable suspension is taining an effective amount of active compound may be suitable for administration once or twice aday whereas formulated using conventional methods and are suitthe oral liquid suspension is suitably administered 2 to able for administration 2 to 4 times a day in the treat- 4 times per day for this purpose. ment of ulcers and pre-ulcer conditions.
Ingredients eig g) liquid suspension 9-phenyll .5-diazabicyclo[4.3.l ]decane 200 I00 sodium carboxy methyl cellulose U.S.P. l.25 12.5 methyl cellulose 0.4 polyvinylpyrrolidone 5 lecithin 3 benzyl alcohol 0.0] magnesium aluminum silicate 47.5 flavor q.s. color q.s. methyl parahen. U.S.P. 4.5 prbpyl paraben. U.S.P. [.0 polysurbatc 80 {c.g. Tween 80), USP 5 sorhitol solution, USP 2,500 buffer agent to adjust pH for desired stability q.s. q.s. water for injection q.s. to 5 ml.
q.s. to l ml.
Ingredient Percent by Weight syrup elixir 9-phenyl-l ,5-diazabicyclo[4.3.l ]decane hydrochloride .53.5 .53.5 Buffering system quantity sufficient to adjust pH Sodium henzoate .l.5 l.5 Flavoring agent .0l.2 .0l.2 Water 2040 5-20 Analogous compositions to those above may be prepared using the hydrochloride salt of 9-(pchlorophenyl)-1,5-diazabicyclo[4.3.l]decane or 9-(pmethoxyphenyl)-l ,5-diazabicyclo[4.3.l ]decane in place of the 9-phenyl-1,5-diazabicyclo[4.3.l]decane hydrochloride.
What is claimed is:
l. A method of treating gastrointestinal ulcers in a mammal, which comprises administering thereto an antr-ulcer effective amount of a compound of the formula:
where R is hydrogen, fluoro, chloro or lower alkoxy or a pharmaceutically acceptable acid addition salt thereof.
2. The method of claim 1 wherein the compound is administered at a daily dosage of from about 60 milligrams to about 1500 milligrams.
3. The method of claim 1 wherein the compound is administered in a unit dosage form comprising from about 15 milligrams to about 750 milligrams of said compound per unit dosage.
4. The method of claim 1 in which the compound is 9-phenyl-l ,5-diazabicyclo[4.3. l ]decane 5. The method of claim 1 in which the compound is 9-(p-chlorophenyl)1 ,5-diazabicyclo[4.3. l ]decane.
6. The method of claim 1 in which the compound is 9-(p-methoxyphenyl)-l ,5-diazabicyclo[4.3.l ]decane.

Claims (6)

1. A METHOD OF TREATING GASTROINTESTINAL ULCERS IN A MAMMAL, WHICH COMPRISES ADMINISTERING THERETO AN ANTI-ULCER EFFECTIVE AMOUNT OF A COMPOUND OF THE FORMULA:
2. The method of claim 1 wherein the compound is administered at a daily dosage of from about 60 milligrams to about 1500 milligrams.
3. The method of claim 1 wherein the compound is administered in a unit dosage form comprising from about 15 milligrams to about 750 milligrams of said compound per unit dosage.
4. The method of claim 1 in which the compound is 9-phenyl-1,5-diazabicyclo(4.3.1)decane.
5. The method of claim 1 in which the compound is 9-(p-chlorophenyl)1,5-diazabicyclo(4.3.1)decane.
6. The method of claim 1 in which the compound is 9-(p-methoxyphenyl)-1,5-diazabicyclo(4.3.1)decane.
US417368A 1973-11-19 1973-11-19 Diazabicyclodecanes as anti-ulcer agents Expired - Lifetime US3867532A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US417368A US3867532A (en) 1973-11-19 1973-11-19 Diazabicyclodecanes as anti-ulcer agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US417368A US3867532A (en) 1973-11-19 1973-11-19 Diazabicyclodecanes as anti-ulcer agents

Publications (1)

Publication Number Publication Date
US3867532A true US3867532A (en) 1975-02-18

Family

ID=23653727

Family Applications (1)

Application Number Title Priority Date Filing Date
US417368A Expired - Lifetime US3867532A (en) 1973-11-19 1973-11-19 Diazabicyclodecanes as anti-ulcer agents

Country Status (1)

Country Link
US (1) US3867532A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517004A (en) * 1967-10-27 1970-06-23 Sandoz Ag Bridged 1,5-diazacyclodecanes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517004A (en) * 1967-10-27 1970-06-23 Sandoz Ag Bridged 1,5-diazacyclodecanes

Similar Documents

Publication Publication Date Title
EP0236684B1 (en) Galanthamine or analogues thereof for treating alzheimer's disease
US4753789A (en) Method for treating nausea and vomiting
US4757072A (en) Carcinostatic agent
US4316888A (en) Method and composition of reducing pain
US4929605A (en) Pharmaceutical composition for piperidinoalkanol derivatives
US5922749A (en) Medicaments for treating nausea and vomiting
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US4766117A (en) Antiinflammatory compositions and methods
US4579846A (en) Antiinflammatory compositions and methods
CA1295251C (en) Propiophenone derivatives for treatment of pollakiuria (frequency urination)
US5362756A (en) Use of fedotozine in the treatment of functional states of intestinal obstructions
US4053617A (en) 2,1,3-benzothiadiazoles as myolonolytics
US3867532A (en) Diazabicyclodecanes as anti-ulcer agents
US5240954A (en) Medicaments
US4212876A (en) Substituted or unsubstituted 2-phenylbenzimidazoles as anti-obesity agents
US20060160887A1 (en) Medicinal composition
US4874757A (en) Antinflammatory compositions and methods
US3924003A (en) Substituted or unsubstituted p-alkanoyl toluenes as anti-obesity and anti-diabetic agents
US3968247A (en) Substituted or unsubstituted p-alkanoyl toluenes as anti-diabetic agents
US3622671A (en) Substituted 3-hydrazino pyridazines as hypotensives
US3714363A (en) Substituted amino guanidine as anti-diabetic agents
US3873708A (en) N-sulfamoyl-substituted-piperidines as anti-tussive agents
US4148906A (en) Growth hormone inhibitors
US3857944A (en) 1-piperazinoisoquinolines as inotropic agents
US4812455A (en) Antiinflammatory compositions and methods